文献速递造血干细胞移植与细胞治疗

MicroRNA-17-92 是小鼠慢性移植物抗宿主病中 T 细胞和 B 细胞致病性所必需的

MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice.
PubMed 文献 · Blood · 2018-03-12

该研究通过条件性敲除小鼠证明,供者 T 细胞和 B 细胞表达 miR-17-92 对慢性移植物抗宿主病(cGVHD)中硬皮病和闭塞性细支气管炎的发生至关重要;在狼疮样 cGVHD 模型中,全身给予 anti-miR-17(而非 anti-miR-19)可减轻临床表现和蛋白尿发生率,并改善硬皮病模型中的皮肤损伤。

要点

  • 供者 T 细胞和 B 细胞表达 miR-17-92 是诱导 cGVHD 硬皮病和闭塞性细支气管炎所必需的。
  • T 细胞中 miR-17-92 促进 Th1、Th17、滤泡辅助性 T 细胞、生发中心 B 细胞和浆细胞生成。
  • 狼疮样 cGVHD 模型中 anti-miR-17 减轻临床表现和蛋白尿,anti-miR-19 无此作用。

核心结论

  • miR-17-92 是 T 细胞和 B 细胞分化与功能以及 cGVHD 发生所必需的。
  • 药理学抑制 miR-17 是预防 cGVHD 的潜在治疗策略。

研究设计与样本

  • 研究生成在 T 细胞、B 细胞或两者中条件性缺陷 miR-17-92 的小鼠,并使用同种异体骨髓移植小鼠模型。
  • 研究还评估了针对 miR-17 或 miR-19 的 antagomir 的转化方法,并在狼疮样 cGVHD 模型和硬皮病-cGVHD 模型中进行测试。

主要发现

  • 供者 T 和 B 细胞表达 miR-17-92 对 cGVHD 中硬皮病和闭塞性细支气管炎的诱导至关重要。
  • T 细胞中 miR-17-92 不仅增强致病性 Th1 和 Th17 细胞分化,还促进滤泡辅助性 T 细胞、生发中心 B 细胞和浆细胞生成。
  • B 细胞中 miR-17-92 表达是自身抗体产生和皮肤免疫球蛋白 G 沉积所必需的。
  • 在狼疮样 cGVHD 模型中,全身给予 anti-miR-17(而非 anti-miR-19)通过抑制供者淋巴细胞扩增、B 细胞活化和生发中心反应,减轻受者临床表现和蛋白尿发生率。
  • 在硬皮病-cGVHD 模型中,阻断 miR-17 通过减少 Th17 分化改善皮肤损伤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic graft-versus-host disease (cGVHD) is characterized as autoimmune-like fibrosis and antibody production mediated by pathogenic T cells and B cells. MicroRNA-17-92 (miR-17-92) influences the survival, differentiation, and function of lymphocytes in cancer, infections, and autoimmunity. To determine whether miR-17-92 regulates T- and B-cell responses in cGVHD, we generated mice conditionally deficient for miR-17-92 in T cells, B cells, or both. Using murine models of allogeneic bone marrow transplantation, we demonstrate that expression of miR-17-92 in donor T and B cells is essential for the induction of both scleroderma and bronchiolitis obliterans in cGVHD. Mechanistically, miR-17-92 expressed in T cells not only enhances the differentiation of pathogenic T helper 1 (Th1) and Th17 cells, but also promotes the generation of follicular Th cells, germinal center (GC) B cells, and plasma cells. In B cells, miR-17-92 expression is required for autoantibody production and immunoglobulin G deposition in the skin. Furthermore, we evaluated a translational approach using antagomirs specific for either miR-17 or miR-19, key members in miR-17-92 cluster. In a lupus-like cGVHD model, systemic administration of anti-miR-17, but not anti-miR-19, alleviates clinical manifestations and proteinuria incidence in recipients through inhibiting donor lymphocyte expansion, B-cell activation, and GC responses. Blockade of miR-17 also ameliorates skin damage by reducing Th17 differentiation in a scleroderma-cGVHD model. Taken together, our work reveals that miR-17-92 is required for T-cell and B-cell differentiation and function, and thus for the development of cGVHD. Furthermore, pharmacological inhibition of miR-17 represents a potential therapeutic strategy for the prevention of cGVHD.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wu Y, Schutt S, Paz K, et al. MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice. Blood. 2018. PMID: 29530952. doi:10.1182/blood-2017-06-789321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。